Lihui Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5524498/publications.pdf

Version: 2024-02-01

33 papers	1,313 citations	304743 22 h-index	395702 33 g-index
33 all docs	33 docs citations	33 times ranked	2070 citing authors

#	Article	IF	Citations
1	DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy. Cancers, 2020, 12, 2123.	3.7	124
2	The combination of disulfiram and copper for cancer treatment. Drug Discovery Today, 2020, 25, 1099-1108.	6.4	95
3	Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity. Cell Death and Disease, 2017, 8, e2746-e2746.	6.3	93
4	Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells. Oncotarget, 2016, 7, 58516-58530.	1.8	84
5	Pterostilbene attenuates lipopolysaccharide-induced learning and memory impairment possibly via inhibiting microglia activation and protecting neuronal injury in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 92-102.	4.8	79
6	Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: An in vitro and in vivo evaluation. Acta Biomaterialia, 2015, 16, 156-168.	8.3	74
7	Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors. Frontiers in Oncology, 2019, 9, 194.	2.8	73
8	Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resistance Updates, 2021, 57, 100770.	14.4	59
9	Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death and Disease, 2018, 9, 129.	6.3	54
10	Novel chalcone derivatives as hypoxia-inducible factor (HIF)-1 inhibitor: Synthesis, anti-invasive and anti-angiogenic properties. European Journal of Medicinal Chemistry, 2015, 89, 88-97.	5.5	50
11	Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer. European Journal of Pharmacology, 2018, 827, 1-12.	3.5	50
12	Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. British Journal of Cancer, 2017, 117, 974-983.	6.4	47
13	Histone methyltransferase and drug resistance in cancers. Journal of Experimental and Clinical Cancer Research, 2020, 39, 173.	8.6	44
14	Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Molecular Cancer, 2020, 19, 134.	19.2	44
15	A novel smallâ€molecule activator of procaspaseâ€3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts. Molecular Oncology, 2014, 8, 1640-1652.	4.6	38
16	Design, synthesis, and structureâ€“activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents. European Journal of Medicinal Chemistry, 2014, 86, 257-269.	5.5	37
17	Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents. European Journal of Medicinal Chemistry, 2014, 81, 47-58.	5.5	32
18	Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer. Cell Death and Disease, 2019, 10, 400.	6.3	29

#	Article	IF	Citations
19	Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach. Oncotarget, 2015, 6, 9740-9755.	1.8	27
20	Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors. Genes, 2018, 9, 633.	2.4	26
21	Epigenetic synthetic lethality approaches in cancer therapy. Clinical Epigenetics, 2019, 11, 136.	4.1	26
22	Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Journal of Medicinal Chemistry, 2021, 64, 5519-5534.	6.4	26
23	Targeting procaspaseâ€3 with <scp>WF</scp>â€208, a novel <scp>PAC</scp>â€1 derivative, causes selective cancer cell apoptosis. Journal of Cellular and Molecular Medicine, 2015, 19, 1916-1928.	3.6	20
24	Epigenetic enzyme mutations as mediators of anti-cancer drug resistance. Drug Resistance Updates, 2022, 61, 100821.	14.4	20
25	An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer. Molecular Cancer, 2022, 21, 106.	19.2	20
26	PAC-1 and its derivative WF-210 Inhibit Angiogenesis by inhibiting VEGF/VEGFR pathway. European Journal of Pharmacology, 2018, 821, 29-38.	3.5	7
27	Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of) Tj ETQq1 1 0.784314 rgBT /Ove	2.8	7
28	Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity inÂvitro and inÂvivo. Chemico-Biological Interactions, 2016, 249, 64-70.	4.0	6
29	The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer. RSC Advances, 2018, 8, 33464-33472.	3.6	6
30	Minor cytotoxic cardenolide glycosides from the root of Streptocaulon juventas. Steroids, 2015, 93, 39-46.	1.8	5
31	5-Hydroxyindole-Based EZH2 Inhibitors Assembled via TCCA-Catalyzed Condensation and Nenitzescu Reactions. Molecules, 2020, 25, 2059.	3.8	5
32	Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC. Bioorganic Chemistry, 2019, 86, 696-704.	4.1	3
33	Multi-functional DNA-conjugated nanohydrogels for aptamer-directed breast cancer cell targeting. New Journal of Chemistry, 2021, 45, 20410-20418.	2.8	3